Does cell therapy and tissue engineering represent a promising treatment of diabetic foot ulcers?

Bratislava Medical Journal

Volumn 111, Issue 3, 2010, Pages 138-143

  Ulicna, M ^a   Danisovic, L ^a   Vojtassak, J ^a  

^a Bratislava   (Slovakia)

Author keywords

Cell therapy; Clinical trials; Diabetic foot ulcer; Tissue engineering

Indexed keywords

BANDAGE; CELL TRANSPLANTATION; DIABETIC FOOT; HUMAN; PATHOPHYSIOLOGY; REVIEW; TISSUE ENGINEERING; WOUND HEALING;

BIOLOGICAL DRESSINGS; CELL TRANSPLANTATION; DIABETIC FOOT; HUMANS; TISSUE ENGINEERING; WOUND HEALING;

EID: 77953072786     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabet Care 2004; 27: 1047-1053.
2. Bartus CL, Margolis DJ. Reducing the incidence of foot ulceration and amputation in diabetes. Curr Diabet Rep 2004; 4: 413-418.
3. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcerus and amputations in diabetes. Diabetes in America. Goverment printing ofi-ce 1995
4. Morris AD, McAlpine R, Steinke D et al. Diabetes and lower-limb amputations in the community: A retrospective cohort study. Diabet Care 1998.21: 738.
5. Wysocki AB. Wound fluids and the pathogenesis of chronic wounds. J Wound Ostomy Continence Nurs 1996; 23: 283-290.
6. Leung PC. Diabetic foot ulcerus - a comprehansive review. Surge on 2007; 5 (4): 219-231.
7. Tam M, Moschella SL. Vascular skin ulcers of limbs. Cardiol Clin 1991; 9: 555-563.
8. Sumpio BE, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin Podiatr Med Surg 2003; 20: 689-708.
9. Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient: prevention and treatment. Vase Health Risk Manag 2007; 3: 65-76.
10. Dormandy JA, Rutherford RB. Managment of peripheral arterial disease (PAD). TASC Worging Group. J Vase Surg 2000; 31: 1-296.
11. Schainefeld RM, Isner JM. Critical limb ischemia: nothing to give at the office? Ann Intern Med 1999; 130: 442-444.
12. Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach.Curr Diabetes Rev 2006; (4): 431-447.
13. Mustoe TA, OShaughnessy K, Klosters O. Chronic wound patho genesis and current treatment strategies: a unifying hypothesis. Plastic Reconstr Surg 2006; 117 (Suppl): 35-41.
14. Liu ZJ, Velazquez OC. Hyperoxia, Endothelial Progenitor Cell Mobilization, and Diabetic Wound Healing. Antioxid Redox Signal 2008; 10(11): 1869-1882.
15. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremi ty ulcers in patients with diabetes from two settings. Diabet Care 1999; 22: 157-162.
16. Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Brith Defects Res Part C Embryo Today 2003; 69: 363-374.
17. Djonov V, Baum O, Burri PH. Vascular remodeling by intussus-ceptive angiogenesis. Cell Tissue Res 2003; 314: 107-117.
18. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004; 117: 3-32.
19. Gailit J, Clark RAF. Studies in vitro on the role of •V and 131 integrins in the adhesion of human dermal fibroblasts to provisional matrix protein fibronectin, vitronectin and fibrinogen. J Invest Dermatol 1996; 106: 102-108.
20. Hassan A, Murata H, Falabella A et al. Dermal fibroblasts from venous ulcerus are unresponsive to the action of TGF-ß1. J dermatol Sci 1997; 16: 59-66.
21. Cooper DM, Yu EZ, Hannessey P et al. Determination of endoge nous cytokines in chronic wound. Ann Surg 1944; 219: 688-692.
22. Duckworth WC, Fawcett J, Reddy S. Insulin-degrading activity in wound fluid. J Clin Endocrinol Metab 2004; 89: 847-851.
23. Wall SJ, Sampson MJ, Level N. Elevated matrix metalloproteina-se-2 and -3 production from human diabetic dermal fibroblasts. Brit J Dermatol 2003; 149: 13-16.
24. Falanga V, Eaglstein WH. The trap hypothesis of venous ulceration. Lancet 1993; 314: 1006-1008.
25. Shen JT, Falanga V. Innovative therapies in wound healing. J Cutaneous Med Surg 2003; 7: 1219-224.
26. Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabet Obes Metab 1999; 5: 265-79.
27. Martin TA, Hilton J, Jiang WG, Harding K. Effect of human-derived dermis on expansion of tissue from venous leg ulcers. Wound Repair Regeneration 2003; 11 (4): 292-296.
28. Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981; 211: 1052-1054.
29. Eaglstein WH, Iriondo M, Laszio K: A composite skin substitute (Graftskin) for surgical wounds: a clinical experience. Dermatol Surg 1995; 21: 839-843.
30. Dinh TL, Veves A. The efficacy of apligraf in the treatment of diabetic foot ulcers. Plastic Reconstr Surg 2006; 117 (7): 152-157.
31. Brem H, Young J, Tomic-Canic M, Isaacs C, Ehrlich HP. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg Technol Int 2003; 11: 23-31.
32. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a Human Skin Equivalent, Is Effective in the Management of Non-infected Neuropathic Diabetic Foot Ulcers. Diabet Care 2001; 24: 290-295.
33. Edmonds M. European and Australian Apligraf Diabetic Foot Ul cer Study Group. Apligraf in the tretment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009; 8 (1): 11-18.
34. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
35. Kues WA, Petersen B, Mysegades W, Carnwath JW, Niemann H. Isolation of murine and porcine fetal stem cells from somatic tissue. Biol Reprod 2005; 72: 1020-1028.
36. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-316.
37. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther 2008; 10: 223.
38. Yamaguchi Y, Yoshida S, Sumikowa Y, Kubo T, Hosojawa K, Ozawa K, Hearing VJ, Yoshikawa K, Hami S. Rapid healing of in tractable diabetic foot ulcers with exposed bones following a novel the rapy of exposing bone marrow cells and then grafting epidermal sheets. Brit J Dermatol 2004; 151 (5): 1019-1028.
39. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther 2003; 10: 621-629.
40. Gruber R, Kandler B, Holzmann P, Vogele-Kadletz M, Losert U, Fischer MB, Watzek G. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng 2005; 11: 896-903.
41. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulat Res 2004; 94: 678-685.
42. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulat Res 1999; 85: 221-228.
43. Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 1992; 116: 435-439.
44. His W. Leoithoblast und angioblast der wirbelthiere. Abhandl K S Ges Wiss Math Phys 1900; 22: 171-328.
45. Weiss MJ, Orkin SH. In vitro differentiation of murine embryonic stem cells. New approaches to old problems. J Clin Invest 1996; 97: 591-595.
46. Kawamoto A, Asahara T. Role of Progenitor Endothelial Cells in Cardiovascular Disease and Upcoming Therapies. Catheterization Cardiovasc Interventions 2007; 70: 477-484.
47. Garlanda C, Dejana E. Heterogeneity of endothelial cells: specific markers. Arterioscler Thromb Vase Biol 1997; 17: 1193-1202.
48. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobi lization, differentiation, and homing. Arterioscler Thromb Vase Biol 2003; 23: 1185-1189.
49. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, Vasculoge nesis, and Induction of healing in chronic wounds. Vase Endovasc Surg 2005; 39 (4): 293-305.
50. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
51. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427.
52. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann NY Acad Sci 2001; 938: 221-229.
53. Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, Schoen FJ, Atala A, Soker S, Bischoff J, Mayer JE Jr. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001; 7: 1035-1040.
54. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
55. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8: 607-612.
56. Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA 2002; 99: 11951-11956.
57. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothe lial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
58. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells. Blood 1997; 90 (12): 5002-5012.
59. Barcelos LS, Duplaa C, Krankel N, Graiani G, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M, Simm A, Campagnolo P, Mangialardi G, Stevanato L, Alessandri G, Emanueli C, Madeddu P. Human CD133+ Progenitor Cells Promote the Healing of Diabetic Ischemic Ulcers by Paracrine Stimulation of Angiogenesis and Activation of Wnt Signaling. Circulat Res 2009; 1524-4571.
60. Gu Y, Zhang J, Qi L. Comparative study on autologous implantation between bone marrow stem cells and peripheral blood stem cells for treatment of lower limb ischemia. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2007; 21 (7): 675-678.
61. Procházka V, Gumulec J, Chmelová J, Klement P, Klement GL, Jonszta T, Czerny D, Krajca J. Autologous bone marrow stem cell transplantation in patients with end-stage chronical critical limb ische mia and diabetic foot. Vnitr Lek 2009; 55 (3): 173-178.
62. Vojtaššák J, Danišovič L, Kubeš M, Bakoš D, Jarábek L, Ulišná M, Blaško M. Autologous biograft and mesenchymal stem cells in tre atment of the diabetic foot. Neuro Endocrinol Lett 2006; 27 (Suppl 2): 134-137.